VEGFA and osteosarcoma: Humanized anti-VEGF monoclonal antibodies, like bevacizumab (Avastin(r)), which was approved by the FDA in February 2004, or ranibizumab (Lucentis(r)), have proven their effectiveness in some cancers, but still not in osteosarcoma.